Twitter
Advertisement

Biocon launches 'Basalog' for adavanced diabetes control

Biotechnology firm Biocon Limited on Friday,launched 'Basalog', a advanced diabetic drug used for treating those suffering from both type one and type two diabetes.

Latest News
article-main
FacebookTwitterWhatsappLinkedin

Biotechnology firm Biocon Limited on Friday, launched 'Basalog', a advanced diabetic drug used for treating those suffering from both type one and type two diabetes. 'Basalog is an advanced diabetic treatment which is effective for 24 hours and can be used by those suffering from both type one and type two diabetes', Kiran Mazumdar-Shaw, CMD, Biocon told reporters during the launch.
    
The key advantage of Basalog is that it replaces other insulins that do not act for 24 hours requiring a diabetic to take multiple shots in a day. Basalog could be used just once in a day, she said. Basalog was a human insulin Glargine to control the
chance of dropping of glucose levels at night. Unlike other insulins which take some time to act and reach peak level and then subside, Basalog ensures that it acts at a constant level for 24 hours, she said.

Moreover, Baslog is effective in HbA1c control, which refers to a diagnostic test to ascertain the patient's blood glucose control for a three-month period. While the HbA1C for normal individual ranges between four to six per cent in diabetic less than seven per cent is considered as an effective control.

Every one per cent of reduction in HbA1c leads to 20 per cent reduction in mortality.  The drug will be available in India starting tomorrow in vials of three ml and 10 ml. "The drug will be priced 40 per cent lower than competitor's drug", she said.
  
It will be priced at less than Rs 500 for a three ml vial, said Rakesh Bamzai, President Marekting, Biocon. "The key focus was ensuring affordable insulin", said Shaw while explaining the reasons for coming up with a three ml vial and pricing it lower than competitors.

"We see a large potential for the drug with a revenue expectation of 500 million USD in less than 10 year period", she said adding that Biocon was also exploring partnership and licensing opportunities with other firms for global markets.
    
The drug would be launched in two years time in major global markets and is expected to reach the US market after 2014, after expiry of the current patent in this market. It
would aim at reaching Europe market through its German arm.
   
Biocon has also tied up with Bayer Polychem India for marketing and distribution of their advanced blood gcluose monitoring system, said Shaw. "We are keen in ofering a comprehensive portfolio in control of diabetes", she said adding "Biocon is engaged and
committed in being an important player in the diabetes care market". The company hopes to complete the comprehensive basket offering once it comes up with the oral insulin.

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed-  Follow DNA on WhatsApp.
Advertisement

Live tv

Advertisement
Advertisement